Collegium Pharmaceutical (NASDAQ:COLL) Sets New 1-Year Low – Time to Sell?

Collegium Pharmaceutical, Inc. (NASDAQ:COLL)’s stock price reached a new 52-week low during trading on Thursday . The stock traded as low as $25.47 and last traded at $25.70, with a volume of 1122273 shares traded. The stock had previously closed at $25.98.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on COLL shares. Needham & Company LLC decreased their price target on shares of Collegium Pharmaceutical from $56.00 to $46.00 and set a “buy” rating for the company in a research report on Thursday, August 6th. Zacks Research lowered shares of Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 28th. Truist Financial raised shares of Collegium Pharmaceutical to a “strong-buy” rating in a research note on Monday, June 15th. Weiss Ratings downgraded Collegium Pharmaceutical from a “hold (c)” rating to a “hold (c-)” rating in a report on Tuesday. Finally, Piper Sandler reaffirmed a “neutral” rating and set a $43.00 target price (down from $45.00) on shares of Collegium Pharmaceutical in a research report on Friday, August 7th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $52.60.

Collegium Pharmaceutical Stock Down 1.1%

The stock’s 50-day moving average price is $34.49 and its 200-day moving average price is $36.57. The company has a current ratio of 1.03, a quick ratio of 0.84 and a debt-to-equity ratio of 3.32. The stock has a market cap of $836.79 million, a price-to-earnings ratio of 20.73 and a beta of 0.73.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings data on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 earnings per share for the quarter, topping the consensus estimate of $1.72 by $0.20. Collegium Pharmaceutical had a net margin of 5.93% and a return on equity of 91.43%. The company had revenue of $199.88 million during the quarter, compared to analysts’ expectations of $199.62 million. During the same period in the prior year, the company posted $1.68 earnings per share. Collegium Pharmaceutical’s revenue for the quarter was up 6.3% compared to the same quarter last year. On average, sell-side analysts expect that Collegium Pharmaceutical, Inc. will post 6.76 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in COLL. BlackRock Inc. acquired a new position in Collegium Pharmaceutical in the second quarter valued at approximately $196,972,000. Rubric Capital Management LP grew its position in shares of Collegium Pharmaceutical by 5.3% during the 2nd quarter. Rubric Capital Management LP now owns 3,157,743 shares of the specialty pharmaceutical company’s stock worth $93,374,000 after buying an additional 157,743 shares during the period. Vanguard Group Inc. increased its stake in shares of Collegium Pharmaceutical by 1.3% in the 4th quarter. Vanguard Group Inc. now owns 2,256,254 shares of the specialty pharmaceutical company’s stock valued at $104,465,000 after acquiring an additional 29,876 shares in the last quarter. Janus Henderson Group PLC increased its stake in shares of Collegium Pharmaceutical by 26.0% in the 1st quarter. Janus Henderson Group PLC now owns 1,825,651 shares of the specialty pharmaceutical company’s stock valued at $60,358,000 after acquiring an additional 377,073 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its position in shares of Collegium Pharmaceutical by 1.1% during the 4th quarter. Renaissance Technologies LLC now owns 1,617,349 shares of the specialty pharmaceutical company’s stock valued at $74,883,000 after acquiring an additional 18,160 shares during the period.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.